Aliases & Classifications for Adenomyosis

MalaCards integrated aliases for Adenomyosis:

Name: Adenomyosis 50
Endometriosis of Uterus 69

Classifications:



Summaries for Adenomyosis

NIH Rare Diseases : 50 adenomyosis is a rare condition that affects the uterus. in affected women, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. some women may have no signs or symptoms of the condition. when present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. some women may also develop an adenomyoma, which is a mass or growth within the uterus. the underlying cause of the condition is currently unknown. in general, treatment is based on the signs and symptoms present in each person. forms of birth control that contain progesterone (such as birth control pills or an iud) may decrease heavy bleeding while certain medications can be used to manage pain. in severe cases, a hysterectomy may be recommended. last updated: 3/15/2017

MalaCards based summary : Adenomyosis, also known as endometriosis of uterus, is related to endometriosis of uterus and cystitis. An important gene associated with Adenomyosis is MMP2 (Matrix Metallopeptidase 2), and among its related pathways/superpathways are GPCR Pathway and Cytokine Signaling in Immune system. The drugs Acetaminophen and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include uterus, endothelial and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 72 Adenomyosis is a gynecologic medical condition characterized by the abnormal presence of endometrial... more...

Related Diseases for Adenomyosis

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 186)
id Related Disease Score Top Affiliating Genes
1 endometriosis of uterus 32.2 ESR1 PGR VEGFA
2 cystitis 30.1 MMP2 MMP9 PGR
3 uterine disease 11.2
4 bartholin's gland benign neoplasm 10.8 ESR1 PGR
5 central nervous system organ benign neoplasm 10.8 ESR1 PGR
6 gallbladder leiomyoma 10.8 ESR1 PGR
7 lung adenoma 10.8 ESR1 PGR
8 glaucoma, hereditary 10.8 ESR1 PGR
9 fallopian tube benign neoplasm 10.8 ESR1 PGR
10 paranasal sinus disease 10.8 ESR1 PGR
11 dartoic leiomyoma 10.8 ESR1 PGR
12 urinary bladder inverted papilloma 10.8 ESR1 PGR
13 spinal cancer 10.8 ESR1 PGR
14 subglottis verrucous carcinoma 10.8 ESR1 PGR
15 facial arteriovenous malformation 10.8 MMP2 MMP9
16 deafness, autosomal dominant 8/12 10.8 ESR1 PGR
17 intestinal perforation 10.8 ESR1 PGR
18 gastric tubular adenocarcinoma 10.8 ESR1 PGR
19 familial short qt syndrome 10.8 MMP2 MMP9
20 her2-receptor positive breast cancer 10.7 ESR1 PGR
21 leucocyte adhesion defect 10.7 MMP2 MMP9
22 acquired hemangioma 10.7 MMP2 MMP9
23 superficial basal cell carcinoma 10.7 ESR1 PGR
24 sarcomatoid squamous cell skin carcinoma 10.7 ESR1 PGR
25 pineal region meningioma 10.7 ESR1 PGR
26 transitional meningioma 10.7 MMP2 MMP9
27 bladder colloid adenocarcinoma 10.7 ESR1 PGR
28 drug rash with eosinophilia and systemic symptoms 10.7 MMP2 MMP9
29 ovarian mesodermal adenosarcoma 10.7 ESR1 PGR
30 diffuse lipomatosis 10.7 PGR VEGFA
31 endophthalmitis 10.7 ESR1 PGR
32 gastroesophageal junction adenocarcinoma 10.7 ESR1 PGR
33 tinea profunda 10.7 MMP2 MMP9
34 osteogenesis imperfecta 10.7 ESR1 PGR
35 chest wall lymphoma 10.7 ESR1 PGR
36 kidney pelvis papillary carcinoma 10.7 MMP9 VEGFA
37 cutaneous mucoepidermoid carcinoma 10.7 ESR1 PGR
38 collagenous colitis 10.7 MMP2 MMP9
39 sialadenitis 10.7 MMP2 MMP9
40 retinal detachment 10.7 ESR1 PGR
41 holoprosencephaly 6 10.7 ESR1 PGR
42 corneal staphyloma 10.7 MMP2 MMP9
43 acute thyroiditis 10.7 ESR1 PGR
44 hepatic vascular disease 10.6 MMP9 VEGFA
45 male reproductive organ cancer 10.6 MMP9 VEGFA
46 retinitis pigmentosa 20 10.6 ESR1 PGR
47 kidney clear cell sarcoma 10.6 ESR1 PGR
48 skin sarcoma 10.6 PGR PRL
49 urethra clear cell adenocarcinoma 10.6 ESR1 PGR
50 nasal cavity adenocarcinoma 10.6 MMP2 MMP9

Graphical network of the top 20 diseases related to Adenomyosis:



Diseases related to Adenomyosis

Symptoms & Phenotypes for Adenomyosis

MGI Mouse Phenotypes related to Adenomyosis:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.24 ESR1 MMP9 NGF OXTR PGR PRL
2 homeostasis/metabolism MP:0005376 10.24 VEGFA ESR1 MMP1 MMP2 MMP9 NGF
3 cardiovascular system MP:0005385 10.18 ESR1 MMP2 MMP9 NGF PGR PTGS2
4 immune system MP:0005387 10.18 ESR1 MMP1 MMP2 MMP9 PGR PRL
5 hematopoietic system MP:0005397 10.11 ESR1 MMP2 MMP9 PGR PTGS2 SPP1
6 integument MP:0010771 10.11 ESR1 MMP9 NGF OXTR PGR PRL
7 muscle MP:0005369 10.09 ESR1 MMP2 MMP9 NGF OXTR PGR
8 nervous system MP:0003631 10.07 SPP1 TIMP2 VEGFA ESR1 MMP2 MMP9
9 neoplasm MP:0002006 10.06 VEGFA ESR1 MMP1 MMP2 MMP9 PGR
10 normal MP:0002873 9.86 ESR1 MMP2 NGF OXTR PGR PTGS2
11 no phenotypic analysis MP:0003012 9.8 ESR1 NGF OXTR PGR PTGS2 VEGFA
12 reproductive system MP:0005389 9.76 ESR1 MMP9 OXTR PGR PRL PTGS2
13 respiratory system MP:0005388 9.43 ESR1 MMP2 MMP9 PTGS2 SPP1 VEGFA
14 skeleton MP:0005390 9.17 ESR1 MMP2 MMP9 PGR PTGS2 SPP1

Drugs & Therapeutics for Adenomyosis

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Ibuprofen Approved Phase 4 15687-27-1 3672
3
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
4 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
5 Analgesics Phase 4,Phase 3
6 Analgesics, Non-Narcotic Phase 4
7 Anti-Inflammatory Agents Phase 4
8 Anti-Inflammatory Agents, Non-Steroidal Phase 4
9 Antipyretics Phase 4
10 Antirheumatic Agents Phase 4
11 Cyclooxygenase Inhibitors Phase 4
12 Ramosetron Approved Phase 3 132036-88-5
13
Goserelin Approved Phase 2, Phase 3 65807-02-5 47725 5311128
14
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
15
Lactitol Investigational Phase 2, Phase 3 585-86-4 3871
16 Antiemetics Phase 3
17 Autonomic Agents Phase 3
18 Gastrointestinal Agents Phase 3
19 Neurotransmitter Agents Phase 3,Phase 1
20
Serotonin Phase 3 50-67-9 5202
21 Serotonin Agents Phase 3
22 Serotonin Antagonists Phase 3
23 Hormone Antagonists Phase 2, Phase 3,Phase 1,Early Phase 1
24 Hormones Phase 2, Phase 3,Phase 1,Early Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1,Early Phase 1
26 Antineoplastic Agents, Hormonal Phase 2, Phase 3
27 Aromatase Inhibitors Phase 2, Phase 3
28 Estrogen Antagonists Phase 2, Phase 3
29 Estrogens Phase 2, Phase 3,Early Phase 1
30 Steroid Synthesis Inhibitors Phase 2, Phase 3
31 Micronutrients Phase 3
32 Trace Elements Phase 3
33
Levonorgestrel Approved, Investigational Phase 2,Early Phase 1 797-63-7, 17489-40-6 13109
34
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
35
Ropivacaine Approved Phase 2 84057-95-4 71273 175805
36 Contraceptive Agents Phase 2,Early Phase 1
37 Contraceptives, Oral Phase 2,Early Phase 1
38 Contraceptives, Oral, Combined Phase 2,Early Phase 1
39 Anesthetics Phase 2
40 Anesthetics, Local Phase 2
41 Anti-Arrhythmia Agents Phase 2
42 Central Nervous System Depressants Phase 2
43 Diuretics, Potassium Sparing Phase 2,Early Phase 1
44 Sodium Channel Blockers Phase 2
45
Bromocriptine Approved, Investigational Phase 1 25614-03-3 31101
46
Dopamine Approved Phase 1 51-61-6, 62-31-7 681
47 Antiparkinson Agents Phase 1
48 Dopamine Agents Phase 1
49 Dopamine agonists Phase 1
50
Menthol Approved 2216-51-5 16666

Interventional clinical trials:

(show top 50) (show all 51)

id Name Status NCT ID Phase Drugs
1 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;IV Placebo
2 Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy Unknown status NCT01483417 Phase 3
3 The Use of Doppler to Diagnose Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
4 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
5 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
6 Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
7 Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
8 Uterine Artery Embolization for Symptomatic Fibroids Completed NCT00354471 Phase 3
9 Efficacy of Trace Elements in the Treatment of Endometriosis: a Pilot Study Active, not recruiting NCT02437175 Phase 3
10 LNG-IUS for Treatment of Dysmenorrhea Unknown status NCT01601366 Phase 2 Combined oral contraceptives
11 Tactile Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding Completed NCT02248194 Phase 2
12 Adenomyosis and Ulipristal Acetate Recruiting NCT02587000 Phase 2 Ulipristal acetate;Placebo
13 Superior Hypogastric Nerve Block for Pain Control Post-UFE Recruiting NCT02270255 Phase 2 0.75% Ropivacaine;1% Xylocaine
14 Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis Withdrawn NCT02794467 Phase 2 Epelsiban;Placebo
15 Vaginal Bromocriptine for Treatment of Adenomyosis Active, not recruiting NCT01821001 Phase 1 Vaginal Bromocriptine
16 Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis Unknown status NCT01259180
17 Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis Unknown status NCT00172588
18 Proliferation of Endometrial Stromal Cells in Adenomyosis Unknown status NCT00173212
19 Health-Related QoL Among Women Receiving Hysterectomy in NTUH Unknown status NCT00155870
20 Progestin Treatment for Endometrial Stromal Cells in Adenomyosis Unknown status NCT00155051
21 To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602
22 The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone (AMH) Unknown status NCT00928044
23 Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy Unknown status NCT01289314
24 Histopathological Diagnosis of Adenomyosis Completed NCT02340533
25 Norwegian Adenomyosis Study I Completed NCT02201719
26 Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis Completed NCT03027648
27 Levonorgestrel Intrauterine System and Adenomyosis Completed NCT03104309
28 New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma Completed NCT02997787
29 Use of Dexamethasone in Uterine Artery Embolization Completed NCT02056717 Dexamethasone;Normal saline
30 Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Completed NCT02192606
31 Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy Completed NCT01806012
32 AMH Levels Change During Treatment With GnRh Agonist Completed NCT02086279 GnRH analogue
33 Surgical Success After Laparoscopic vs Abdominal Hysterectomy Completed NCT01793584
34 Electronic Catheter Stethoscope Completed NCT01463462
35 Sonohysterography , 3D Ultrasonography and Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility Completed NCT02399501
36 The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms Recruiting NCT02495311
37 Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Recruiting NCT03037944 Early Phase 1 Yasmin
38 A Prospective Study of Diagnostic Accuracy of Ultrasound Recruiting NCT03120078
39 Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Recruiting NCT03302468
40 Cooperative Adenomyosis Network Recruiting NCT03230994
41 Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Recruiting NCT02914704
42 Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Recruiting NCT02086344
43 Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis Recruiting NCT03006406 Long term GnRH-a (3.75mg)
44 Effect of Salpingectomy During Conservative Hysterectomy Recruiting NCT01628432
45 Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Active, not recruiting NCT02197923
46 Norwegian Adenomyosis Study III: Peristalsis Active, not recruiting NCT02197936
47 What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Active, not recruiting NCT01992718 Early Phase 1
48 High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Enrolling by invitation NCT02954757
49 Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Not yet recruiting NCT02556411 LNG-IUS 13,5 mg Levonorgestrel;Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
50 Acceptability and Tolerance of Hysteroscopy and Hysterosonography in Consultation Not yet recruiting NCT03121560

Search NIH Clinical Center for Adenomyosis

Genetic Tests for Adenomyosis

Anatomical Context for Adenomyosis

MalaCards organs/tissues related to Adenomyosis:

39
Uterus, Endothelial, Testes, Pituitary, Brain, Monocytes, Cervix

Publications for Adenomyosis

Articles related to Adenomyosis:

(show top 50) (show all 678)
id Title Authors Year
1
Safety of ultrasound-guided high-intensity focused ultrasound ablation for diffuse adenomyosis: A retrospective cohort study. ( 28069193 )
2017
2
Changes in anti-mA1llerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid. ( 28856867 )
2017
3
Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. ( 28927080 )
2017
4
Unique Learning System for Uterine Artery Embolization for Symptomatic Myoma and Adenomyosis for Obstetrician-Gynecologists in Cooperation with Interventional Radiologists: Evaluation of UAE From the Point of View of Gynecologists Who Perform UAE. ( 28807810 )
2017
5
Title: Hysteroscopic Removal of Retained Products of Conception Implanted Over a Focal Area of Adenomyosis. a Case Report. ( 28939480 )
2017
6
Rhein ameliorates adenomyosis by inhibiting NF-I_B and I^-Catenin signaling pathway. ( 28763746 )
2017
7
Quercetin alleviates generalized hyperalgesia in mice with induced adenomyosis. ( 28849202 )
2017
8
The Expression of Toll-like receptors in eutopic and ectopic endometrium and its implication in the inflammatory pathogenesis of adenomyosis. ( 28779087 )
2017
9
The Role of Hysteroscopy in the Diagnosis and Treatment of Adenomyosis. ( 28852646 )
2017
10
Immunohistochemical Parameters of Musashi-1 in Nodular and Diffuse Adenomyosis. ( 28853072 )
2017
11
Downregulation of DNA methyltransferase 3 alpha promotes cell proliferation and invasion of ectopic endometrial stromal cells in adenomyosis. ( 27986572 )
2017
12
Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. ( 28911934 )
2017
13
A comparison of the cost-utility of ultrasound-guided high-intensity focused ultrasound and hysterectomy for adenomyosis: a retrospective study. ( 28856866 )
2017
14
Gonadotrophin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study. ( 28856862 )
2017
15
The impact of adenomyosis on the outcome of IVF-embryo transfer. ( 28802706 )
2017
16
Decreased expression of interleukin-37 in the ectopic and eutopic endometria of patients with adenomyosis. ( 28762845 )
2017
17
Transvaginal Ultrasound for the Diagnosis of Adenomyosis: Systematic Review and Meta-Analysis. ( 28864044 )
2017
18
The effect of exercise on high-intensity focused ultrasound treatment efficacy in uterine fibroids and adenomyosis: a retrospective study. ( 28856860 )
2017
19
Ultrasound-guided transcervical radiofrequency ablation for symptomatic uterine adenomyosis. ( 27792415 )
2017
20
Concomitant use of transvaginal sonography and Doppler indices improve diagnosis of adenomyosis. ( 28766365 )
2017
21
T2 relaxometry mapping in demonstrating layered uterine architecture: parameter optimisation and utility in endometrial carcinoma and adenomyosis: A feasibility study. ( 28936889 )
2017
22
A Rare Case of Intramural MA1llerian Adenosarcoma Arising from Adenomyosis of the Uterus. ( 28741605 )
2017
23
Abnormal expression of Nrf2 may play an important role in the pathogenesis and development of adenomyosis. ( 28817677 )
2017
24
Serum Osteopontin Levels Are Decreased in Focal Adenomyosis. ( 27678100 )
2017
25
Effects of adenomyosis on inA vitro fertilization treatment outcomes: a meta-analysis. ( 28865548 )
2017
26
The Role of Adenomyosis in the Pathogenesis of Preeclampsia. ( 27582582 )
2016
27
Spontaneous conception following GnRHa and progestogen therapy in adenomyosis. ( 26812802 )
2016
28
Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease. ( 27645154 )
2016
29
Outcomes in Adenomyosis Treated with Uterine Artery Embolization Are Associated with Lesion Vascularity: A Long-Term Follow-Up Study of 252 Cases. ( 27806072 )
2016
30
The effect of adenomyosis on the outcomes of laparoscopic hysterectomy. ( 27651723 )
2016
31
The role of pathologic evaluation of endometrial ablation resections in predicting ablation failure and adenomyosis in hysterectomy. ( 27461823 )
2016
32
Rare Case of Leiomyoma and Adenomyosis in Mayer-Rokitansky-Kuster-Hauser Syndrome. ( 27843659 )
2016
33
Focal adenomyosis (intramural endometriotic cyst) in a very young patient - differential diagnosis with uterine fibromatosis. ( 27453751 )
2016
34
Monochorionic twin delivery after conservative surgical treatment of a patient with severe diffuse uterine adenomyosis without uterine rupture. ( 27462599 )
2016
35
LPS/TLR4-mediated stromal cells acquire an invasive phenotype and are implicated in the pathogenesis of adenomyosis. ( 26898650 )
2016
36
Expression of Inflammatory and Neurogenic Mediators in Adenomyosis: A Pathogenetic Role. ( 27440813 )
2016
37
Effect of matrix metalloproteinase promoter polymorphisms on endometriosis and adenomyosis risk: evidence from a meta-analysis. ( 27659332 )
2016
38
Authors' Response: Expression of CD56 in patients with adenomyosis and its correlation with dysmenorrhea. ( 27889198 )
2016
39
Immunohistochemical expression pattern of metastasis suppressor KISS-1 protein in adenomyosis lesions and normal endometrium. ( 27940396 )
2016
40
UTERINE ADENOMYOSIS AND AN ENDOMETRIAL POLYP IN A ROCK HYRAX (PROCAVIA CAPENSIS). ( 28080921 )
2016
41
Increased expression of Talin1 in the eutopic and ectopic endometria of women with adenomyosis. ( 26759065 )
2016
42
The Significance of MRI Evaluation of the Uterine Junctional Zone in the Early Diagnosis of Adenomyosis. ( 27147800 )
2016
43
Proangiogenic features in chronic pelvic pain caused by adenomyosis. ( 27759451 )
2016
44
Treatment strategies for pelvic pain associated with adenomyosis. ( 27759444 )
2016
45
Live birth in a woman with recurrent implantation failure and adenomyosis following transfer of refrozen-warmed embryos. ( 27689042 )
2016
46
Clinical Predictors of Long-term Success in Ultrasound-guided High-intensity Focused Ultrasound Ablation Treatment for Adenomyosis: A Retrospective Study. ( 26817877 )
2016
47
Temporarily Blocking the Uterine Artery to Dig Out a Diffused Adenomyosis Lesion Treated Laparoscopically. ( 27702702 )
2016
48
Spontaneous conception and two successful pregnancies in patient who underwent conservative surgical management of diffuse uterine adenomyosis. ( 27153393 )
2016
49
Role of benign ovarian cysts in the development of adenomyosis. ( 27570851 )
2016
50
Increased expression of nuclear factor kappa-B p65 subunit in adenomyosis. ( 27004203 )
2016

Variations for Adenomyosis

Expression for Adenomyosis

Search GEO for disease gene expression data for Adenomyosis.

Pathways for Adenomyosis

Pathways related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 32)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.56 ESR1 MMP1 MMP2 MMP9 NGF PTGS2
2
Show member pathways
13.2 MMP1 MMP2 MMP9 PRL PTGS2 VEGFA
3
Show member pathways
12.65 ESR1 NGF PTGS2 VEGFA
4
Show member pathways
12.59 MMP1 MMP2 MMP9 SPP1 TIMP2
5 12.54 NGF PRL PTGS2 SPP1 VEGFA
6 12.49 MMP1 MMP2 MMP9 PTGS2 VEGFA
7 12.18 ESR1 MMP2 MMP9 VEGFA
8 12.01 ESR1 MMP1 VEGFA
9 11.95 MMP2 MMP9 VEGFA
10
Show member pathways
11.83 ESR1 PGR PRL
11 11.77 MMP1 MMP2 MMP9 PTGS2 VEGFA
12
Show member pathways
11.7 MMP1 MMP2 MMP9 TIMP2
13 11.61 MMP2 MMP9 PTGS2 TIMP2
14 11.59 MMP9 SPP1 VEGFA
15 11.57 MMP2 MMP9 SPP1
16 11.52 MMP9 PTGS2 VEGFA
17 11.49 MMP1 MMP2 MMP9 VEGFA
18 11.44 MMP1 PTGS2 VEGFA
19 11.41 MMP1 MMP2 MMP9 PTGS2 VEGFA
20 11.4 ESR1 PTGS2 VEGFA
21
Show member pathways
11.35 MMP2 MMP9 SPP1
22 11.34 MMP1 MMP2 MMP9 TIMP2
23 11.28 MMP1 MMP9 TIMP2
24 11.18 MMP1 MMP2 MMP9
25 11.06 MMP2 MMP9
26 11.05 MMP9 TIMP2
27 11.05 ESR1 MMP2 MMP9
28 10.99 MMP9 TIMP2 VEGFA
29 10.96 MMP1 MMP2
30 10.91 MMP1 VEGFA
31 10.85 MMP1 MMP9
32
Show member pathways
10.82 MMP1 MMP2 MMP9 PTGS2 VEGFA

GO Terms for Adenomyosis

Cellular components related to Adenomyosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 MMP1 MMP2 MMP9 NGF PRL SPP1
2 extracellular matrix GO:0031012 9.46 MMP1 MMP2 MMP9 TIMP2
3 proteinaceous extracellular matrix GO:0005578 9.02 MMP1 MMP2 MMP9 TIMP2 VEGFA

Biological processes related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 response to estradiol GO:0032355 9.63 ESR1 OXTR PTGS2
2 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.58 NGF PTGS2 VEGFA
3 endodermal cell differentiation GO:0035987 9.56 MMP2 MMP9
4 cellular protein metabolic process GO:0044267 9.56 MMP1 MMP2 PRL SPP1
5 decidualization GO:0046697 9.55 PTGS2 SPP1
6 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.54 MMP2 MMP9
7 collagen catabolic process GO:0030574 9.54 MMP1 MMP2 MMP9
8 response to vitamin D GO:0033280 9.52 PTGS2 SPP1
9 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.51 OXTR PTGS2
10 response to cytokine GO:0034097 9.5 OXTR PTGS2 TIMP2
11 macrophage differentiation GO:0030225 9.49 MMP9 VEGFA
12 mammary gland alveolus development GO:0060749 9.48 ESR1 VEGFA
13 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.43 PTGS2 VEGFA
14 lactation GO:0007595 9.33 OXTR PRL VEGFA
15 embryo implantation GO:0007566 9.26 MMP2 MMP9 PTGS2 SPP1
16 extracellular matrix disassembly GO:0022617 9.02 MMP1 MMP2 MMP9 SPP1 TIMP2

Molecular functions related to Adenomyosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 metallopeptidase activity GO:0008237 9.43 MMP1 MMP2 MMP9
2 steroid binding GO:0005496 9.37 ESR1 PGR
3 extracellular matrix binding GO:0050840 9.32 SPP1 VEGFA
4 metalloendopeptidase inhibitor activity GO:0008191 9.16 NGF TIMP2
5 metalloendopeptidase activity GO:0004222 9.13 MMP1 MMP2 MMP9
6 zinc ion binding GO:0008270 9.02 ESR1 MMP1 MMP2 MMP9 PGR

Sources for Adenomyosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....